This Week in Pediatrics — Aug 3, 2026

Welcome to This Week in Pediatrics. This week we are covering ten notable papers spanning neonatal and early-life interventions, pediatric therapeutic safety, and adolescent mental health and chronic care. We will explore how common therapies like paracetamol and anesthesia might affect long-term development, examine the real-world performance of biologic biosimilars, and dissect how environmental factors like community violence shape adolescent mental health trajectories. Let us dive in.

We begin in the neonatal intensive care unit, where two new studies challenge our current management strategies. First, a secondary analysis of the BeNeDuctus trial published in Pediatric Research investigates the pulmonary safety of paracetamol in extremely preterm infants [1]. While paracetamol is increasingly favored as an analgesic and an alternative to non-steroidal anti-inflammatory drugs for closing a patent ductus arteriosus, preclinical data have raised concerns about its impact on lung development. In this study, researchers evaluated two hundred and seventy-three infants born at less than twenty-eight weeks of gestation. They categorized the infants into four groups based on their drug exposure: paracetamol alone, ibuprofen alone, both drugs, or no exposure, which served as the control group. Using multivariable logistic regression adjusted for key confounders, the investigators found that exposure to paracetamol alone was associated with a more than threefold increase in the odds of developing moderate-to-severe bronchopulmonary dysplasia, with an adjusted odds ratio of 3.22. Interestingly, ibuprofen alone also nearly tripled the risk, and the combination of both drugs was associated with a nearly fourfold increase in the odds of moderate-to-severe bronchopulmonary dysplasia. These findings highlight that paracetamol, despite its reputation for safety, may pose significant risks to the developing lungs of extremely preterm infants, demanding a rigorous re-evaluation of its use for both pain and ductus arteriosus management. In the same journal, Pediatric Research, researchers explored another common neonatal intervention: probiotic supplementation, and its effect on the fecal antibiotic resistome [7]. Antimicrobial resistance is a critical global threat, and preterm infants are particularly vulnerable to multi-drug resistant sepsis. This systematic review compiled data from eighteen studies involving nearly thirty-five hundred neonates to see if probiotics could limit the colonization of resistance genes. Ten of the eighteen included studies reported a significant reduction in the prevalence of the fecal antibiotic resistome among infants receiving probiotics. Interestingly, five of the eight studies that found no reduction relied on older culture or polymerase-chain-reaction-based methods rather than advanced metagenomic sequencing, which may have limited their sensitivity. While the overall certainty of the evidence was rated as low to very low, these findings suggest that targeted probiotic strategies could serve as a valuable tool to complement antibiotic stewardship in neonatal intensive care units.

Moving from neonatal interventions to prenatal influences, another study in Pediatric Research highlights how maternal nutrition can alter the long-term developmental trajectory of the offspring [6]. Gestational diabetes mellitus is a well-known risk factor for offspring neurodevelopmental delay, driven by intrauterine hyperglycemia and fetal hyperinsulinemia. In this prospective birth cohort of over seventy-four hundred pregnant women, researchers sought to determine if maternal vitamin D status could modify this risk. They measured maternal serum twenty-five-hydroxyvitamin D levels at sixteen to twenty-three weeks of gestation, assessed gestational diabetes and insulin resistance at twenty-four to twenty-eight weeks, and measured umbilical cord blood C-peptide levels at delivery. The offspring were then screened for neurodevelopmental delays up to thirty-six months of age. Overall, gestational diabetes was associated with a twenty-six percent higher risk of neurodevelopmental delay in the offspring. However, when the researchers stratified the cohort by maternal vitamin D status, a striking pattern emerged. Among women who were vitamin D deficient, defined as levels below fifty nanomoles per liter, gestational diabetes was associated with a thirty-four percent higher risk of neurodevelopmental delay and a thirty-nine percent higher risk of fetal hyperinsulinemia. In sharp contrast, these elevated risks were completely absent in women who had sufficient vitamin D levels. Fetal hyperinsulinemia and maternal insulin resistance were also strongly correlated only in the vitamin D-deficient group. This prospective data suggests that maintaining adequate maternal vitamin D levels during pregnancy might serve as a simple, highly modifiable protective factor that disrupts the intergenerational transmission of glucose dysregulation and shields the fetal brain from the adverse effects of gestational diabetes.

Next, we turn to the safety and efficacy of therapeutic interventions in older infants and children, starting with a comprehensive narrative review of pediatric anesthesia and the developing brain published in The Lancet Child and Adolescent Health [2]. For years, clinicians and parents have grappled with preclinical evidence showing that common anesthetic agents can disrupt neurodevelopmental processes during critical developmental windows. This review synthesizes the clinical evidence from the last several years to provide clear guidance. Randomized controlled trials offer reassuring evidence that a single, brief exposure to general anesthesia during infancy does not lead to measurable cognitive impairment in childhood. However, observational data remain mixed. Large, population-based studies have consistently identified a small but statistically significant increase in the risk of attention-deficit hyperactivity disorder following early anesthesia exposure. Additionally, emerging evidence suggests there may be subtle, long-term changes in visual processing and development, though these findings are still preliminary. The authors emphasize that because of confounding factors like the underlying surgery and childhood comorbidities, a direct causal link is difficult to establish. When counseling families, pediatricians should acknowledge parental anxiety but emphasize that necessary surgical procedures should never be delayed due to theoretical neurodevelopmental risks, as maintaining physiological stability during essential procedures remains the priority. Reassurance also comes from a study in the Journal of Pediatric Gastroenterology and Nutrition, which examined the real-world efficacy of infliximab biosimilars compared to the originator biologic in children with inflammatory bowel disease [8]. Utilizing data from the ImproveCareNow registry, researchers performed a propensity score-matched analysis of four hundred and twenty-eight children initiating either the originator or a biosimilar. After matching for age, sex, race, initiation year, and disease type, the two groups showed remarkably similar outcomes at twelve months. There were no statistically significant differences in steroid-free clinical remission, height z-scores, hematocrit, albumin, or erythrocyte sedimentation rates. Furthermore, the time to drug discontinuation, surgery, and hospitalization was comparable between the groups. While fecal calprotectin levels were slightly higher in the biosimilar group at twelve months, this finding was limited by the fact that only thirty percent of the cohort had calprotectin data available. This study, one of the largest of its kind in pediatrics, provides robust evidence that infliximab biosimilars are just as effective and durable as the originator, supporting their use as a safe, cost-effective option for pediatric inflammatory bowel disease.

We also received reassuring safety data regarding rotavirus immunization from a systematic review published in Acta Paediatrica [5]. This review analyzed eighty-six studies published since 2007 to evaluate gastrointestinal adverse events following the administration of the RV1 and RV5 vaccines in children. The authors found that while mild, transient symptoms like self-limiting diarrhea and vomiting are common, there was no increased risk of prolonged diarrhea, intussusception, or chronic immune-mediated conditions like celiac disease or inflammatory bowel disease in healthy infants. However, the study highlighted that certain high-risk groups, including infants with a history of intussusception, severe combined immunodeficiency, or metabolic disorders, experience significantly higher rates of adverse events. Crucially, the authors note that in high-income settings, if a child develops prolonged, severe diarrhea after receiving a rotavirus vaccine, this should not be dismissed as a standard side effect. Instead, it should serve as an important clinical marker for an underlying, previously undiagnosed severe immunodeficiency, prompting immediate diagnostic evaluation.

Our final theme transitions to adolescent health, chronic disease management, and the social determinants of health, beginning with a powerful study in Pediatrics that links community violence with youth mental health trends [3]. While much attention has been paid to the rise in youth depression and suicide during the COVID-19 pandemic, this cross-sectional study of over seventy-one thousand adolescent well visits in Philadelphia from 2017 to 2024 examined what happened as pandemic-era restrictions eased and community firearm violence fluctuated. Overall, adolescent depression rates returned to pre-pandemic levels, but suicide risk remained elevated, particularly among non-Hispanic Black and Medicaid-insured youth. Strikingly, this trajectory was heavily moderated by local levels of firearm violence. In neighborhoods classified as firearm violence cold spots, youth suicide risk actually declined by over two percentage points post-pandemic. Conversely, in neutral areas, suicide risk rose by nearly one percentage point, and in violence hot spots, suicide risk increased by two percentage points. This clear divergence demonstrates that the trauma and chronic stress of living in communities plagued by firearm violence prevent the post-pandemic recovery of youth mental health. It underscores that pediatricians must look beyond universal screening tools and actively address persistent, localized environmental stressors when supporting adolescent mental health.

Managing chronic disease and its psychological burden is another major focus this week. A pilot study in Latvia, published in the European Journal of Pediatrics, evaluated a screening program for pre-symptomatic type 1 diabetes among high-risk pediatric populations [9]. Latvia has seen rising rates of type 1 diabetes, with nearly half of newly diagnosed children presenting in life-threatening diabetic ketoacidosis. In this prospective study, researchers screened eighty-three siblings of children with type 1 diabetes. Over thirty-one percent tested positive for at least one autoantibody during initial screening. Upon secondary testing for all four diagnostic autoantibodies, five children were found to have two or more positive autoantibodies. During a relatively short follow-up period of ten to twenty-four months, three of these five children progressed to stage two or stage three type 1 diabetes, representing a positive predictive value of sixty percent. While the clinical benefits of early detection are clear, the study also measured parental anxiety and depression. Parents of children who screened positive experienced significantly higher rates of severe anxiety compared to those with negative results. This highlights that while screening can successfully identify pre-symptomatic diabetes and prevent diabetic ketoacidosis, clinicians must be prepared to provide robust psychological support to these families. Meanwhile, another study in the European Journal of Pediatrics investigated the lived experiences of children with obesity and their parents [10]. While clinical research often focuses on long-term cardiovascular and metabolic risks, this prospective study of children visiting a specialized obesity center focused on immediate, self-reported health complaints and social impacts. An overwhelming eighty-seven percent of children reported significant social challenges, most commonly difficulty finding fitting clothes, mobility issues, and bullying. Furthermore, over ninety-two percent reported physical health complaints, with abdominal pain, headaches, and musculoskeletal pain topping the list, particularly among adolescent girls. Alarmingly, the perceived effectiveness of lifestyle interventions, such as consulting with a dietitian, was rated extremely low, with scores ranging between zero and four on a ten-point scale. This dissatisfaction was most pronounced among children with more severe obesity. This stark disconnect between current treatment models and the daily struggles of these children calls for a more holistic, compassionate, and patient-centered framework that addresses immediate physical pain and social isolation alongside weight management.

Finally, addressing systemic barriers to health begins in infancy, as outlined in a new policy statement from the American Academy of Pediatrics published in Pediatrics [4]. The statement emphasizes that pediatricians are uniquely positioned to dismantle the racial disparities that persist in breastfeeding and the use of human milk. These disparities are rooted in systemic racism and implicit bias, which affect the quality of lactation support provided to families of color. The policy outlines evidence-based solutions, including building strong partnerships with community health workers, implementing culturally centered hospital practices, and advocating for fair insurance reimbursement for lactation services and supplies. Furthermore, the statement calls on pediatricians to eliminate commercial milk formula marketing within their clinical spaces, which disproportionately targets vulnerable populations. By actively engaging with these resources and adopting equitable care practices, pediatricians can play a crucial role in ensuring that all infants, regardless of race, have access to the protective benefits of human milk.

If you only have time for one paper this week, make it the secondary analysis of the BeNeDuctus trial in Pediatric Research exploring paracetamol and bronchopulmonary dysplasia [1]. This study challenges our long-held assumptions about the safety of paracetamol in extremely preterm infants, revealing a more than threefold increase in the odds of moderate-to-severe bronchopulmonary dysplasia and signaling an urgent need to re-evaluate our neonatal pain and patent ductus arteriosus management strategies.

Here are the key takeaways from this week in Pediatrics. First, paracetamol use in extremely preterm infants may not be as benign as previously assumed, with data showing a significant association with moderate-to-severe bronchopulmonary dysplasia. Second, in pregnant women with gestational diabetes, maintaining adequate vitamin D levels may completely eliminate the associated risk of offspring neurodevelopmental delay and fetal hyperinsulinemia. Third, community firearm violence acts as a major driver of persistent youth suicide risk, meaning mental health screening must be integrated with an understanding of neighborhood trauma. Fourth, infliximab biosimilars demonstrate equivalent twelve-month clinical efficacy, durability, and safety compared to the originator biologic for children with inflammatory bowel disease. And finally, prolonged diarrhea following rotavirus vaccination in high-income settings should prompt an immediate evaluation for underlying severe immunodeficiency rather than being dismissed as a common vaccine reaction.

That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.